JPRN-UMIN000051975尚未招募未知
Optimal therapeutic strategies with CDK4/6 inhibitors based on the real world evidence in patients with HR-positive/HER2-negative advanced and metastatic breast cancer - JBCRG-C10
Japan Breast Cancer Research Group(JBCRG)0 个研究点目标入组 400 人开始时间: 2023年8月25日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18years-old 至 ot applicable（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
不适用
Fulvestrant and CDK4/6 inhibitor as first line hormonal therapy for locally advanced/ metastatic disease for Patients with Hormone receptor positive HER2 negative breast cancer -observational studybreast cancerJPRN-UMIN000035533Setouchi Breast Project Comprehensive Support Organization75
进行中（未招募）
1 期
Endocrine therapy plus CDK4/6 inhibitor in first or second line for hormone receptor positive advanced breast cancerhormone receptor positive advanced breast cancerEUCTR2017-002334-23-NLDutch Breast Cancer Research Group (BOOG)1,050
已完成
不适用
Selecteren van de optimale plaats van CDK4/6-remmer bij de behandeling van uitgezaaide hormoongevoelige (HR+) borstkanker: de SONIA studiebreast cancerNL-OMON23699BOOG study center1,050
已完成
3 期
Selecting the Optimal position of CDK4/6 Inhibitors in HR+ Advanced breast cancer: the SONIA trialMammary carcinoma10006291Breast cancerNL-OMON53036BOOG Study Center1,050
进行中（未招募）
1 期
Inhibition of kinases CDK4/6 by Palbociclib in locally advanced/metastatic chordomaEUCTR2016-004660-19-DEniversity Hospital Heidelberg43